open access

Vol 24, No 2 (2019)
Original research articles
Published online: 2019-03-01
Submitted: 2018-09-18
Get Citation

Radiopotentiation of enzalutamide over human prostate cancer cells as assessed by real-time cell monitoring

Marta Barrado, Idoia Blanco-Luquin, Paola Andrea Navarrete, Ignacio Visus, David Guerrero-Setas, David Escors, Grazyna Kochan, Fernando Arias
DOI: 10.1016/j.rpor.2019.02.002
·
Rep Pract Oncol Radiother 2019;24(2):221-226.

open access

Vol 24, No 2 (2019)
Original research articles
Published online: 2019-03-01
Submitted: 2018-09-18

Abstract

Aim

To evaluate the radiopotentiation of enzalutamide in human prostate cancer cells.

Background

While radiotherapy is the first line of treatment for prostate cancer, androgen blockade therapies are demonstrating significant survival benefit as monotherapies. As androgen blockade can cause cell death by apoptosis, it is likely that androgen blockade will potentiate the cytotoxic activities of radiotherapy.

Materials and methods

Here, we tested the potential synergistic effects of these two treatments over two human metastatic prostate cancer cells by real-time cell analysis (RTCA), androgen-sensitive LNCaP cells (Lymph Node Carcinoma of the Prostate) and androgen-independent PC-3. Both cell lines were highly resistant to high doses of radiotherapy.

Results

A pre-treatment of LNCaP cells with IC50 concentrations of enzalutamide significantly sensitized them to radiotherapy through enhanced apoptosis. In contrast, enzalutamide resistant PC-3 cells were not sensitized to radiotherapy by androgen blockade.

Conclusions

These results provide evidence that the enzalutamide/radiotherapy combination could maximize therapeutic responses in patients with enzalutamide-sensitive prostate cancer.

Abstract

Aim

To evaluate the radiopotentiation of enzalutamide in human prostate cancer cells.

Background

While radiotherapy is the first line of treatment for prostate cancer, androgen blockade therapies are demonstrating significant survival benefit as monotherapies. As androgen blockade can cause cell death by apoptosis, it is likely that androgen blockade will potentiate the cytotoxic activities of radiotherapy.

Materials and methods

Here, we tested the potential synergistic effects of these two treatments over two human metastatic prostate cancer cells by real-time cell analysis (RTCA), androgen-sensitive LNCaP cells (Lymph Node Carcinoma of the Prostate) and androgen-independent PC-3. Both cell lines were highly resistant to high doses of radiotherapy.

Results

A pre-treatment of LNCaP cells with IC50 concentrations of enzalutamide significantly sensitized them to radiotherapy through enhanced apoptosis. In contrast, enzalutamide resistant PC-3 cells were not sensitized to radiotherapy by androgen blockade.

Conclusions

These results provide evidence that the enzalutamide/radiotherapy combination could maximize therapeutic responses in patients with enzalutamide-sensitive prostate cancer.

Get Citation

Keywords

Enzalutamide; Radiotherapy; Apoptosis; Prostate cancer; Androgen blockade

About this article
Title

Radiopotentiation of enzalutamide over human prostate cancer cells as assessed by real-time cell monitoring

Journal

Reports of Practical Oncology and Radiotherapy

Issue

Vol 24, No 2 (2019)

Pages

221-226

Published online

2019-03-01

DOI

10.1016/j.rpor.2019.02.002

Bibliographic record

Rep Pract Oncol Radiother 2019;24(2):221-226.

Keywords

Enzalutamide
Radiotherapy
Apoptosis
Prostate cancer
Androgen blockade

Authors

Marta Barrado
Idoia Blanco-Luquin
Paola Andrea Navarrete
Ignacio Visus
David Guerrero-Setas
David Escors
Grazyna Kochan
Fernando Arias

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk, Poland
tel.:+48 58 320 94 94, fax:+48 58 320 94 60, e-mail: journals@viamedica.pl